UC's Office of the Chief Investment Officer has backed a new immuno-oncology startup that has licensed 17 assets from Pfizer.
US-based immuno-oncology drug developer Allogene Therapeutics has launched with $300m in series A financing from investors including University of California’s Office of the Chief Investment Officer of the Regents.
The round was also backed by pharmaceutical firm Pfizer, which is providing assets for the startup, as well as private equity group TPG, life sciences-focused venture capital firm Vida Ventures and BellCo Capital.
Pfizer will own a 25% equity stake in Allogene following the deal, which is expected to close by…
